目的分析静疗干预联合信息化行为干预对老年急性白血病经外周静脉置入中心静脉导管(peripherally inserted central catheter,PICC)置管后不良反应及生活质量的影响。方法选取2019年2月-2020年12月在四川大学华西医院治疗并行PICC术的10...目的分析静疗干预联合信息化行为干预对老年急性白血病经外周静脉置入中心静脉导管(peripherally inserted central catheter,PICC)置管后不良反应及生活质量的影响。方法选取2019年2月-2020年12月在四川大学华西医院治疗并行PICC术的103例老年急性白血病患者作为分析对象,按照随机数字表法将其分为联合组与对照组,其中对照组51例患者实施常规护理,联合组52例患者在常规护理基础上实施静疗联合信息化行为干预。记录2组不良反应发生情况,比较护理前、护理3个月后2组患者自我健康认知[健康促进生活方式量表(health promoting lifestyle profile,HPLP)]、心理状态[症状自评量表(symptom checklist 90,SCL-90)]、治疗依从性、生活质量[生活质量指数(quality of life index,QLI)]d变化情况。结果联合组患者不良反应总发生率低于对照组(P<0.05)。护理3个月后,2组患者治疗总依从率均高于同组护理前,且联合组高于对照组(P<0.05);2组患者HPLP各维度评分、QLI各项目评分高于同组护理前,且2组护理前后差数比较差异有统计学意义(P<0.05);2组患者SCL-90各项目评分均低于护理前,且2组护理前后差数比较差异有统计学意义(P<0.05)。结论静疗联合信息化行为干预可有效降低老年急性白血病患者PICC置管后不良反应发生率,改善不良心理状态,增强自我健康认知及治疗依从性,提高生活质量。展开更多
Objective: To investigate the clinical efficacy of venetoclax in the treatment of elderly acute myeloid leukemia (AML). Methods: 50 cases of elderly AML patients receiving venetoclax for treatment in the hospital from...Objective: To investigate the clinical efficacy of venetoclax in the treatment of elderly acute myeloid leukemia (AML). Methods: 50 cases of elderly AML patients receiving venetoclax for treatment in the hospital from January 2022 to January 2024 were selected, including 38 cases of patients whose primary treatment was not suitable for intensive chemotherapy and 12 cases of relapsed/refractory AML patients, to observe the therapeutic efficacy and safety of venetoclax. Results: Among the 38 patients whose primary treatment was not suitable for intensive chemotherapy, 5 cases were treated with venetoclax monotherapy, 33 cases were treated with venetoclax + azacitidine, and 25 patients (65.79%) achieved complete remission (CR) with incomplete hematologic recovery (CRi) after 28 days of treatment;10 patients with relapsed/refractory AML were treated with venetoclax + azacitidine, and 2 patients were treated with venetoclax + azacitidine + chemotherapy, and 2 patients achieved optimal therapeutic response after 28 days of treatment and CR/CRi was achieved in 7 patients (58.33%). There were 47 (94.0%) patients with grade 3 or higher granulocytopenia, 46 (92.0%) patients with hemoglobin reduction, and 43 (86.0%) patients with thrombocytopenia, developed after 28 days of treatment. 11 patients developed infections after treatment and there was one case of tumor lysis syndrome. Conclusion: The response rate of venetoclax monotherapy and combination in elderly AML induction therapy is high, and the overall tolerability of elderly patients is good, so it can be popularized and applied.展开更多
文摘目的分析静疗干预联合信息化行为干预对老年急性白血病经外周静脉置入中心静脉导管(peripherally inserted central catheter,PICC)置管后不良反应及生活质量的影响。方法选取2019年2月-2020年12月在四川大学华西医院治疗并行PICC术的103例老年急性白血病患者作为分析对象,按照随机数字表法将其分为联合组与对照组,其中对照组51例患者实施常规护理,联合组52例患者在常规护理基础上实施静疗联合信息化行为干预。记录2组不良反应发生情况,比较护理前、护理3个月后2组患者自我健康认知[健康促进生活方式量表(health promoting lifestyle profile,HPLP)]、心理状态[症状自评量表(symptom checklist 90,SCL-90)]、治疗依从性、生活质量[生活质量指数(quality of life index,QLI)]d变化情况。结果联合组患者不良反应总发生率低于对照组(P<0.05)。护理3个月后,2组患者治疗总依从率均高于同组护理前,且联合组高于对照组(P<0.05);2组患者HPLP各维度评分、QLI各项目评分高于同组护理前,且2组护理前后差数比较差异有统计学意义(P<0.05);2组患者SCL-90各项目评分均低于护理前,且2组护理前后差数比较差异有统计学意义(P<0.05)。结论静疗联合信息化行为干预可有效降低老年急性白血病患者PICC置管后不良反应发生率,改善不良心理状态,增强自我健康认知及治疗依从性,提高生活质量。
文摘Objective: To investigate the clinical efficacy of venetoclax in the treatment of elderly acute myeloid leukemia (AML). Methods: 50 cases of elderly AML patients receiving venetoclax for treatment in the hospital from January 2022 to January 2024 were selected, including 38 cases of patients whose primary treatment was not suitable for intensive chemotherapy and 12 cases of relapsed/refractory AML patients, to observe the therapeutic efficacy and safety of venetoclax. Results: Among the 38 patients whose primary treatment was not suitable for intensive chemotherapy, 5 cases were treated with venetoclax monotherapy, 33 cases were treated with venetoclax + azacitidine, and 25 patients (65.79%) achieved complete remission (CR) with incomplete hematologic recovery (CRi) after 28 days of treatment;10 patients with relapsed/refractory AML were treated with venetoclax + azacitidine, and 2 patients were treated with venetoclax + azacitidine + chemotherapy, and 2 patients achieved optimal therapeutic response after 28 days of treatment and CR/CRi was achieved in 7 patients (58.33%). There were 47 (94.0%) patients with grade 3 or higher granulocytopenia, 46 (92.0%) patients with hemoglobin reduction, and 43 (86.0%) patients with thrombocytopenia, developed after 28 days of treatment. 11 patients developed infections after treatment and there was one case of tumor lysis syndrome. Conclusion: The response rate of venetoclax monotherapy and combination in elderly AML induction therapy is high, and the overall tolerability of elderly patients is good, so it can be popularized and applied.
